Literature DB >> 33800021

Luteal Support with very Low Daily Dose of Human Chorionic Gonadotropin after Fresh Embryo Transfer as an Alternative to Cycle Segmentation for High Responders Patients Undergoing Gonadotropin-Releasing Hormone Agonist-Triggered IVF.

Andrea Roberto Carosso1, Stefano Canosa1, Gianluca Gennarelli1, Marta Sestero1, Bernadette Evangelisti1, Lorena Charrier2, Loredana Bergandi3, Chiara Benedetto1, Alberto Revelli1.   

Abstract

The segmentation of the in vitro fertilization (IVF) cycle, consisting of the freezing of all embryos and the postponement of embryo transfer (ET), has become popular in recent years, with the main purpose of preventing ovarian hyperstimulation syndrome (OHSS) in patients with high response to controlled ovarian stimulation (COS). Indeed cycle segmentation (CS), especially when coupled to a GnRH-agonist trigger, was shown to reduce the incidence of OHSS in high-risk patients. However, CS increases the economic costs and the work amount for IVF laboratories. An alternative strategy is to perform a fresh ET in association with intensive luteal phase pharmacological support, able to overcome the negative effects of the GnRH-agonist trigger on the luteal phase and on endometrial receptivity. In order to compare these two strategies, we performed a retrospective, real-life cohort study including 240 non-polycystic ovarian syndrome (PCO) women with expected high responsiveness to COS (AMH >2.5 ng/mL), who received either fresh ET plus 100 IU daily human chorionic gonadotropin (hCG) as luteal support (FRESH group, n = 133), or cycle segmentation with freezing of all embryos and postponed ET (CS group, n = 107). The primary outcomes were: implantation rate (IR), live birth rate (LBR) after the first ET, and incidence of OHSS. Overall, significantly higher IR and LBR were observed in the CS group than in the FRESH group (42.9% vs. 27.8%, p < 0.05 and 32.7% vs. 19.5%, p < 0.05, respectively); the superiority of CS strategy was particularly evident when 16-19 oocytes were retrieved (LBR 42.2% vs. 9.5%, p = 0.01). Mild OHSS appeared with the same incidence in the two groups, whereas moderate and severe OHSS forms were observed only in the FRESH group (1.5% and 0.8%, respectively). In conclusion, in non-PCO women, high responders submitted to COS with the GnRH-antagonist protocol and GnRH-agonist trigger, CS strategy was associated with higher IR and LBR than the strategy including fresh ET followed by luteal phase support with a low daily hCG dose. CS appears to be advisable, especially when >15 oocytes are retrieved.

Entities:  

Keywords:  GnRH agonist trigger; GnRH antagonist protocol; IVF; corpus luteum function; hCG; luteal phase support; ovarian hyperstimulation syndrome

Year:  2021        PMID: 33800021      PMCID: PMC7998839          DOI: 10.3390/ph14030228

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  42 in total

1.  The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting.

Authors: 
Journal:  Hum Reprod       Date:  2011-04-18       Impact factor: 6.918

2.  Elective frozen replacement cycles for all: ready for prime time?

Authors:  A Maheshwari; S Bhattacharya
Journal:  Hum Reprod       Date:  2012-11-11       Impact factor: 6.918

3.  Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience.

Authors:  C Yding Andersen; R Fischer; V Giorgione; Thomas W Kelsey
Journal:  J Assist Reprod Genet       Date:  2016-07-22       Impact factor: 3.412

4.  The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome.

Authors:  C Albert; N Garrido; A Mercader; C V Rao; J Remohí; C Simón; A Pellicer
Journal:  Mol Hum Reprod       Date:  2002-05       Impact factor: 4.025

5.  Perinatal morbidity after in vitro fertilization is lower with frozen embryo transfer.

Authors:  Suleena Kansal Kalra; Sarah J Ratcliffe; Lauren Milman; Clarisa R Gracia; Christos Coutifaris; Kurt T Barnhart
Journal:  Fertil Steril       Date:  2011-02       Impact factor: 7.329

6.  Luteinizing hormone affects uterine receptivity independently of ovarian function.

Authors:  Jan Tesarik; André Hazout; Carmen Mendoza
Journal:  Reprod Biomed Online       Date:  2003 Jul-Aug       Impact factor: 3.828

7.  The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.

Authors:  Samuel Santos-Ribeiro; Shari Mackens; Biljana Popovic-Todorovic; Annalisa Racca; Nikolaos P Polyzos; Lisbet Van Landuyt; Panagiotis Drakopoulos; Michel de Vos; Herman Tournaye; Christophe Blockeel
Journal:  Hum Reprod       Date:  2020-12-01       Impact factor: 6.918

8.  Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome.

Authors:  D J Amor; J X Xu; J L Halliday; I Francis; D L Healy; S Breheny; H W G Baker; A M Jaques
Journal:  Hum Reprod       Date:  2009-02-26       Impact factor: 6.918

9.  Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.

Authors:  J Neulen; Z Yan; S Raczek; K Weindel; C Keck; H A Weich; D Marmé; M Breckwoldt
Journal:  J Clin Endocrinol Metab       Date:  1995-06       Impact factor: 5.958

10.  Controlled ovarian stimulation and progesterone supplementation affect vaginal and endometrial microbiota in IVF cycles: a pilot study.

Authors:  Andrea Carosso; Alberto Revelli; Gianluca Gennarelli; Stefano Canosa; Stefano Cosma; Fulvio Borella; Annalisa Tancredi; Carlotta Paschero; Lara Boatti; Elisa Zanotto; Francesca Sidoti; Paolo Bottino; Cristina Costa; Rossana Cavallo; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2020-07-15       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.